Featured Clinical Trials
Featured Clinical Trial for Alpha-1 Antitrypsin Deficiency (AATD)
If you have been diagnosed with Alpha-1 Antitrypsin Deficiency, you may be eligible to participate in a study to check the safety of Fazirsiran and learn if Fazirsiran can help people with liver disease and scarring (Fibrosis) due to an abnormal version of Alpha-1 Antitrypsin Protein.
Featured Clinical Trial for Hepatocellular Carcinoma (HCC)
If you have been diagnosed with Hepatocellular Carcinoma (HCC), you may be eligible to participate a U.S. study to evaluate Transarterial Radioembolization (TARE) in combination with Durvalumab and Bevacizumab Therapy in people with unresectable Hepatocellular Carcinoma amenable to TARE (EMERALD-Y90).
Featured Clinical Trial for Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH).